Significant morbidity and mortality are found in the immunemediated haematological disorders autoimmune haemolytic anaemia (AIHA) and idiopathic thrombocytopenic purpura (ITP). Despite the availability of several treatment options, relapsed or refractory disease is frequently encountered and treatment-related complications are of major concern.
secondary AIHA, associated with an underlying factor such as a lymphoproliferative condition, autoimmune disorder, infection or medication regimen. 3 ITP is characterised by immune-mediated platelet destruction in the mononuclear phagocytic system, leading to thrombocytopenia. As with AIHA, ITP can be divided into primary (idiopathic) and secondary ITP. 4 Evans syndrome is a rare disorder defined by a combination of immune thrombocytopenia and anaemia and without any known underlying condition. 5 Although major progress has been made during the last few decades, the pathogenesis of immune-mediated disorders remains poorly understood. The role of T cells has been established for a long time, but B cells also seem to play a major role, being responsible for the production of autoantibodies, but also by acting as antigen-presenting cells (APCs) supporting the activation of autoreactive T cells. This major contribution of B cells makes them an attractive target in the treatment of immune-mediated disorders and provides a rationale for the use of rituximab in AIHA and ITP (see Figure 1) . 3, 6 In warm antibody AIHA, corticosteroids are the initial therapy In a non-urgent setting, corticosteroids remain the initial standard treatment. In cases of intolerance, IV anti-D can be considered in Rh+ patients. However, more than 70% of patients fail to achieve a lasting response with these agents. In these cases, splenectomy is the standard of care. This leads to a durable response in about two-thirds of patients. In refractory or relapsing patients, immunosuppressive therapy including azathioprine, cyclophosphamide, cyclopsporin A, mycophenolate mofetil and combinations of these products has shown variable responses. 8 In recent years, several reports using monoclonal antibodies 
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Depletion of B cells by rituximab seems to be a result of complementdependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity and induction of apoptosis. 9 Based on the current literature, rituximab seems to have efficacy in the treatment of AIHA. Unfortunately, most of the available evidence is based on case reports or single-centre experiences. A few prospective trials have been performed, but none of them included a control group. In addition, response criteria were not uniform or were not mentioned. Nevertheless, as shown in Table 1 , rituximab seems to be an effective and safe therapy. Overall response rates with rituximab approached 78%.
Response duration ranged from one to 96 months. 10 Especially in cold agglutinin disease, rituximab seems to be a promising agent, improving therapeutic responses compared with classic agents, with overall response rates of 45-60%. However, there were few complete remissions. Nevertheless, these are promising results due to the current lack of effective therapies in this subtype of AIHA. 11, 12 Additionally, rituximab can be combined with cytotoxic agents in the treatment of AIHA secondary to CLL or other lymphoproliferative disorders. 13 Several studies have shown that rituximab may also show impressive Table 2 , rituximab was associated with a platelet count response in approximately 64% of patients. Response duration ranged from five to 48 months. 10 Despite these promising results, prospective randomised trials are needed to determine response rates, duration of responses, prognostic factors predicting response, exact timing, doses and safety.
Although toxicity appears low, caution is needed. Most common side effects are infusion-related, such as fever, chills, headache, rash, bronchospasm and hypotension, mostly occurring during the first infusion. After administration of rituximab, peripheral B cell levels show a dramatic decrease, returning to near baseline six to 12 months after completion of therapy. Despite this profound B-cell depletion, decrease in serum Ig levels is observed in only a minority of patients. Serious infections seem to be rare and are seen only when concomitant immunosuppressive therapy is given. 15 However, rituximab needs to be used with caution in patients with a history of hepatitis B because of the risk of hepatitis activation. 16 Finally, T cells are not affected by rituximab, giving the patients no excess susceptibility to opportunistic infections compared with other MAbs such as alemtuzumab. 15 Analogous to the use of rituximab in the treatment of B-cell malignancies, rituximab was given at a dose of 375mg/m 2 /week over four consecutive weeks in most cases. Responses were mainly seen four to eight weeks after the start of rituximab administration, supporting the concept of depletion of autoreactive B cells as the main mechanism of action. However, in some cases responses were observed during the first few weeks after start of rituximab. This may have been due to saturation of Fc receptors of the mononuclear phagocytic system by Preliminary experience suggests that re-treatment with rituximab in patients relapsing after a successful treatment with anti-CD20 therapy is beneficial, although concern has been raised.
Platelet (THR) and red blood cell (RBC) antigens are cleaved by antigen-presenting cells (APCs) and presented as peptides on their surface via major histocompatibility complex (MHC) class II molecules. This complex is recognised by the T-cell receptor (TCR) of the CD4-positive T-helper (Th)-cell. Additional co-stimulatory signals are provided by CD80-CD28 and CD40-CD154 interactions. The activated Th cells produce activating cytokines (such as interleukin-2 and interferon-γ), which cause activation and differentiation of B-cells, leading to autoantibody production. Autoantigens on the surface of THRs and
Reactivation of the disease may be attributable to the production of autoantibodies by long-lived plasma cells that are not targeted by rituximab due to the absence of CD20 expression on their surface. 2 Apart from rituximab, other targeted immunotherapy has been described in immune-mediated haematological disorders.
Alemtuzumab is a humanised rat anti-CD52 MAb that binds to Although a phase I trial showed encouraging results, no further trials were set up because of the occurrence of unacceptable adverse (thromboembolic) events. 18 Based on growing literature and experience, rituximab has emerged as an effective and well-tolerated immunotherapeutic treatment option in patients with immune anaemia and thrombocytopenia.
However, due to the lack of controlled data, no conclusions regarding the true efficacy, optimal timing, dose and safety of rituximab administration can currently be made and no valid comparison with the classic treatments of immune cytopenia is currently available. ■
